A groundbreaking small-scale clinical trial from Brazil, published in the Journal of Alzheimer’s Disease, provides the first human evidence that microdosing cannabis extract can stabilize—and in some cases slightly improve—cognitive function in patients with mild Alzheimer’s disease.
Researchers recruited 24 elderly participants aged 60 to 80, randomly assigning them to receive either a daily oral oil containing extremely low, balanced doses of THC (about 0.35 mg) and CBD (about 0.245 mg) or a placebo for 26 weeks.
These sub-psychoactive amounts are far below recreational levels, producing no intoxicating “high” or notable side effects. The primary measure was the Mini-Mental State Examination (MMSE), a standard 30-point test assessing orientation, memory, attention, and language.
Over the trial period, the cannabis group maintained stable MMSE scores, with a slight average improvement of around 0.67 points, while the placebo group experienced the typical decline of about 1-2 points expected in untreated mild Alzheimer’s.
This resulted in a statistically significant between-group difference of roughly 1.7 to 3 points, considered clinically meaningful since untreated patients often lose 3–4 MMSE points annually. No major differences emerged in secondary outcomes or adverse events, indicating good tolerability.
The findings build on preclinical data suggesting cannabinoids reduce neuroinflammation, protect neurons, and modulate amyloid or tau pathology, though exact mechanisms in humans remain under study. As the longest trial to date testing low-dose cannabinoids in Alzheimer’s, it marks an unprecedented step forward.
However, with only 24 participants, results are preliminary; larger, longer trials are essential to confirm whether this approach can meaningfully slow disease progression or become a viable therapy.
Leave a Comment